Silence Therapeutics reported positive Phase II trial results for divesiran, an siRNA targeting TMPRSS6 in polycythemia vera (PV). The SANRECO trial met its primary endpoint, with an 88% response rate versus 19% in placebo-controlled groups, according to the company’s announcement. The company framed the results as a path to more consistent hematocrit control while reducing reliance on phlebotomy, which is burdensome for PV patients and linked to real-world tolerability issues. Silence also highlighted that treated patients reached long intervals without phlebotomy, with some dosing as infrequent as every three months. Clinically, PV response durability and thrombotic event reduction remain the key decision points for whether siRNA can move beyond hematologic control into outcome-level benefit. The next steps will likely include confirmatory development discussions and longer follow-up safety and durability readouts.